Compare KVYO & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KVYO | ICUI |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | 2023 | 1995 |
| Metric | KVYO | ICUI |
|---|---|---|
| Price | $21.07 | $179.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 23 | 8 |
| Target Price | $27.08 | ★ $194.25 |
| AVG Volume (30 Days) | ★ 4.8M | 228.8K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.29 | ★ 100.62 |
| EPS | N/A | ★ 3.02 |
| Revenue | $1,234,019,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $24.48 | N/A |
| Revenue Next Year | $19.21 | $4.27 |
| P/E Ratio | $657.67 | ★ $57.37 |
| Revenue Growth | ★ 31.63 | N/A |
| 52 Week Low | $12.53 | $113.37 |
| 52 Week High | $33.36 | $192.85 |
| Indicator | KVYO | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 64.24 |
| Support Level | $15.09 | $153.75 |
| Resistance Level | $21.24 | $191.07 |
| Average True Range (ATR) | 1.03 | 7.20 |
| MACD | 0.01 | 1.39 |
| Stochastic Oscillator | 59.27 | 93.49 |
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.